{
  "id": "nccn_ipi",
  "title": "National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)",
  "description": "Predicts survival in patients with diffuse large B-cell lymphoma (DLBCL) using age, LDH levels, extranodal involvement, Ann Arbor stage, and ECOG performance status. Developed for the rituximab era with enhanced prognostic discrimination.",
  "category": "hematology",
  "version": "2014",
  "parameters": [
    {
      "name": "age",
      "type": "integer",
      "required": true,
      "description": "Patient age in years",
      "validation": {
        "min": 18,
        "max": 120
      },
      "unit": "years"
    },
    {
      "name": "ldh_ratio",
      "type": "float",
      "required": true,
      "description": "LDH (lactate dehydrogenase) ratio compared to upper limit of normal (ULN). Calculate as: patient's LDH / upper limit of normal",
      "validation": {
        "min": 0.1,
        "max": 20
      },
      "unit": "ratio"
    },
    {
      "name": "extranodal_sites",
      "type": "string",
      "required": true,
      "description": "Presence of extranodal disease in major organs (bone marrow, CNS, liver/GI tract, or lung)",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "ann_arbor_stage",
      "type": "string",
      "required": true,
      "description": "Ann Arbor staging for lymphoma",
      "options": ["I", "II", "III", "IV"],
      "validation": {
        "enum": ["I", "II", "III", "IV"]
      }
    },
    {
      "name": "ecog_performance_status",
      "type": "integer",
      "required": true,
      "description": "ECOG performance status (0 = Fully active, 1 = Restricted in strenuous activity, 2 = Ambulatory but unable to work, 3 = Limited self-care, 4 = Completely disabled)",
      "validation": {
        "min": 0,
        "max": 4
      }
    }
  ],
  "result": {
    "name": "nccn_ipi_score",
    "type": "integer",
    "unit": "points",
    "description": "NCCN-IPI total score (0-8 points)"
  },
  "interpretation": {
    "ranges": [
      {
        "min": 0,
        "max": 1,
        "stage": "Low",
        "description": "Low risk",
        "interpretation": "5-year overall survival: 96%. Excellent prognosis with standard R-CHOP chemotherapy. Consider clinical trials for de-escalation strategies."
      },
      {
        "min": 2,
        "max": 3,
        "stage": "Low-Intermediate",
        "description": "Low-intermediate risk",
        "interpretation": "5-year overall survival: 82%. Good prognosis with standard therapy. Standard R-CHOP remains appropriate."
      },
      {
        "min": 4,
        "max": 5,
        "stage": "High-Intermediate",
        "description": "High-intermediate risk",
        "interpretation": "5-year overall survival: 64%. Moderate prognosis. Consider intensified therapy or clinical trials for novel agents."
      },
      {
        "min": 6,
        "max": 8,
        "stage": "High",
        "description": "High risk",
        "interpretation": "5-year overall survival: 33%. Poor prognosis with standard therapy. Strong consideration for intensive therapy, autologous stem cell transplant, or clinical trials."
      }
    ]
  },
  "references": [
    "Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 6;123(6):837-42.",
    "Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020 Jun 4;135(23):2041-2048.",
    "Gleeson M, Hawkes EA, Peckitt C, Wotherspoon A, Attygalle A, Sharma B, et al. Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. Br J Haematol. 2021 Feb;192(6):1015-1019."
  ],
  "formula": "NCCN-IPI Score = Age points + LDH points + Extranodal sites (1 if yes) + Ann Arbor stage (1 if III/IV) + ECOG status (1 if ≥2)\n\nAge: ≤40 (0), >40-60 (1), >60-75 (2), >75 (3)\nLDH: Normal (0), >1-3× ULN (1), ≥3× ULN (2)",
  "notes": [
    "Developed specifically for patients treated in the rituximab era",
    "Extranodal sites refer to involvement of bone marrow, CNS, liver/GI tract, or lung only",
    "Provides better discrimination than conventional IPI for low and high-risk patients",
    "Maximum score is 8 points, minimum is 0 points",
    "Should be used at initial diagnosis before treatment initiation"
  ]
}